PinnyPeptide

Cartalax vs Vesugen

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Cartalax

Bioregulators

Khavinson short peptide bioregulator targeting chondrocytes and connective tissue.

Peptide B

Vesugen

Bioregulators

Khavinson short peptide bioregulator targeting vascular endothelium — KED tripeptide.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Cartalax effects

  • Reported support of chondrocyte function and cartilage matrix synthesis
  • Improvements in joint pain and mobility (Russian observational)
  • Possible slowing of age-related cartilage degradation
  • Recovery support after cartilage injury
  • Modulation of connective-tissue gene expression

Vesugen effects

  • Reported improvement in endothelial function (flow-mediated dilation)
  • Reduction in arterial stiffness measures
  • Anti-inflammatory effects on vascular endothelium
  • Modulation of vascular gene expression
  • Support of nitric oxide synthesis

Cartalax side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation

Vesugen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Should not substitute for proven cardiovascular therapies

Cartalax dosing ranges

Joint / cartilage support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Vesugen dosing ranges

Vascular health support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Cartalax guide → Full Vesugen guide →

Cartalax vs Vesugen — common questions

What is the difference between Cartalax and Vesugen?

Cartalax: Khavinson short peptide bioregulator targeting chondrocytes and connective tissue. Typical dose 1,000-5,000 mcg. Vesugen: Khavinson short peptide bioregulator targeting vascular endothelium — KED tripeptide. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Cartalax and Vesugen?

Stacking Cartalax with Vesugen is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Cartalax or Vesugen?

Cartalax is typically dosed: Once daily (SubQ) or sublingual for Joint / cartilage support. Vesugen is typically dosed: Once daily (SubQ) or sublingual for Vascular health support.

Are Cartalax and Vesugen FDA approved?

Cartalax: Not FDA approved. Vesugen: Not FDA approved.

Related peptide comparisons

bronchogen vs cartalaxcardiogen vs cartalaxcartalax vs cortagencartalax vs crystagencartalax vs ovagencartalax vs pancragen

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free